Pelosi Rx Pricing Bill Offers Big Savings, Big Drop In Drug Development – CBO

Overall effect on health of US families stemming from increased use of drugs but decreased availability of new drugs is 'unclear,' the Congressional Budget Office concludes in its preliminary analysis of HR 3.

Capitol Building, Washington DC

More from Pricing Debate

More from Market Access